Thermo Fisher Scientific, Expression Pathology to improve identification of cancer-related proteins
Thermo Fisher Scientific Inc. also announced in December a collaboration between its Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center and Expression Pathology Inc.
SAN JOSE, Calif.—Thermo Fisher Scientific Inc. alsoannounced in December a collaboration between its Biomarker ResearchInitiatives in Mass Spectrometry (BRIMS) Center and Expression Pathology Inc.,a Rockville, Md.-based tissue proteomic analysis firm.
The collaboration willapply Thermo Fisher's expertise in quantitative protein analysis using massspectrometry and Expression Pathology's patented Director lasermicrodissection and Liquid Tissue sample processingtechnologies to accurately measure cancer-related proteins in formalin-fixedparaffin-embedded (FFPE) tissue. The goal of the partnership is to develop aworkflow that is more sensitive and provides high-quality, quantitativeinformation about a much wider range of specific proteins that are suspected ofbeing markers for cancer. Financial terms of the collaboration were notreleased.